Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis (Shanghai Sine Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Shanghai Xinyi Bailuda Pharmaceutical
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacteria Triple Viable Capsule (marketed as Pefeikan) is a probiotic combination product containing live *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. It is primarily used to treat intestinal dysbiosis and associated gastrointestinal disorders such as diarrhea, constipation, and abdominal distension. The mechanism involves the colonization of the intestinal tract with beneficial bacteria, which produce organic acids, lower intestinal pH, and inhibit the growth of pathogenic microorganisms. Recent clinical research, such as studies by Shanghai Sixth People's Hospital, explores its role in modulating the lung–gut axis to improve outcomes in conditions like pulmonary fibrosis by influencing systemic immune markers and microbiota composition.
- Brand names
- PefeikanBIFICO
- Other names
- Bifidobacteria Triple Viable CapsuleBifidobacterium Triple Viable CapsulePefeikangBifidobacterium, Lactobacillus and Enterococcus Triple Viable Capsules
Beyond the preview
Go deeper on bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis (Shanghai Sine Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis (Shanghai Sine Pharmaceutical).